Compare PKOH & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKOH | HUMA |
|---|---|---|
| Founded | 1907 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.3M | 324.0M |
| IPO Year | N/A | N/A |
| Metric | PKOH | HUMA |
|---|---|---|
| Price | $21.21 | $1.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.13 |
| AVG Volume (30 Days) | 32.9K | ★ 5.0M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | ★ 2.42% | N/A |
| EPS Growth | ★ 30.26 | N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $1,592,500,000.00 | $1,571,000.00 |
| Revenue This Year | $0.23 | N/A |
| Revenue Next Year | $3.07 | $1,468.13 |
| P/E Ratio | $9.94 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.52 | $1.09 |
| 52 Week High | $33.19 | $6.77 |
| Indicator | PKOH | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 60.73 | 47.79 |
| Support Level | $18.69 | $1.09 |
| Resistance Level | $20.50 | $1.26 |
| Average True Range (ATR) | 0.74 | 0.11 |
| MACD | 0.19 | 0.03 |
| Stochastic Oscillator | 98.20 | 76.50 |
Park-Ohio Holdings Corp is a company, engaged in industrial supply chain logistics and diversified manufacturing business. It operates in three business segments namely Supply Technologies, Assembly Components and Engineered Products. Geographically, the business of the group is amplifying across the region of the United States, Asia, Europe, Canada, Mexico and others. The company derives key revenue from the Supply Technologies segment which includes proactive solutions approach that manages the efficiencies of every aspect of supplying production parts and materials to customers' manufacturing floor, from strategic planning to program implementation.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.